ZA202209989B - A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof - Google Patents

A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Info

Publication number
ZA202209989B
ZA202209989B ZA2022/09989A ZA202209989A ZA202209989B ZA 202209989 B ZA202209989 B ZA 202209989B ZA 2022/09989 A ZA2022/09989 A ZA 2022/09989A ZA 202209989 A ZA202209989 A ZA 202209989A ZA 202209989 B ZA202209989 B ZA 202209989B
Authority
ZA
South Africa
Prior art keywords
therapy
nirogacestat
bcma
directed
combination therapy
Prior art date
Application number
ZA2022/09989A
Other languages
English (en)
Inventor
Webster Shearer Todd
Edris Badreddin
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of ZA202209989B publication Critical patent/ZA202209989B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
ZA2022/09989A 2020-03-13 2022-09-07 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof ZA202209989B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062989372P 2020-03-13 2020-03-13
PCT/US2021/022177 WO2021183934A1 (en) 2020-03-13 2021-03-12 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Publications (1)

Publication Number Publication Date
ZA202209989B true ZA202209989B (en) 2025-12-17

Family

ID=75396879

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2022/09989A ZA202209989B (en) 2020-03-13 2022-09-07 A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof

Country Status (17)

Country Link
US (1) US20230121547A1 (https=)
EP (1) EP4132515A1 (https=)
JP (2) JP7781764B2 (https=)
KR (1) KR20230009873A (https=)
CN (1) CN115916188A (https=)
AR (1) AR121566A1 (https=)
AU (1) AU2021236340A1 (https=)
BR (1) BR112022018251A2 (https=)
CA (1) CA3171267A1 (https=)
CL (1) CL2022002479A1 (https=)
CO (1) CO2022014388A2 (https=)
IL (1) IL296075A (https=)
MX (1) MX2022011258A (https=)
PE (1) PE20230614A1 (https=)
TW (1) TW202200132A (https=)
WO (1) WO2021183934A1 (https=)
ZA (1) ZA202209989B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3230245A1 (en) 2021-09-01 2023-03-09 Springworks Therapeutics, Inc. Synthesis of nirogacestat
WO2023064872A1 (en) * 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
CN118338900A (zh) * 2021-11-05 2024-07-12 斯普林渥克斯治疗有限公司 含尼罗加司他的组合物和治疗
CN118302412A (zh) * 2021-11-23 2024-07-05 梯瓦制药国际有限责任公司 Nirogacestat盐的固态形式
US12138246B2 (en) 2022-05-20 2024-11-12 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
IL316750A (en) 2022-05-20 2025-01-01 Springworks Therapeutics Inc Treatments with Nirogesstat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
EP4678635A1 (en) * 2023-03-09 2026-01-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of nirogacestat dihydrobromate, and preparation method therefor and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149855B2 (en) * 2014-02-05 2018-12-11 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides
AU2016297793A1 (en) * 2015-07-24 2018-02-08 Oncotracker, Inc. Gamma secretase modulators for the treatment of immune system dysfunction
IL268349B2 (en) * 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018201056A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN110622566B (zh) 2017-05-05 2021-04-20 华为技术有限公司 一种辅助数据传输方法、设备及系统
SG11202003427XA (en) * 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
WO2019094626A1 (en) * 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies
US20210069194A1 (en) * 2018-01-17 2021-03-11 Mingsight Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
SG11202011589WA (en) * 2018-05-24 2020-12-30 Ayala Pharmaceuticals Inc Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
UY38251A (es) * 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
BR112021020409A2 (pt) * 2019-04-10 2021-12-07 Glaxosmithkline Ip Dev Ltd Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase
EP4010322B1 (en) 2019-08-09 2025-11-05 Pfizer Inc. Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Also Published As

Publication number Publication date
JP2025168430A (ja) 2025-11-07
WO2021183934A1 (en) 2021-09-16
CA3171267A1 (en) 2021-09-16
PE20230614A1 (es) 2023-04-14
MX2022011258A (es) 2023-01-11
TW202200132A (zh) 2022-01-01
JP2023517243A (ja) 2023-04-24
BR112022018251A2 (pt) 2022-11-08
CO2022014388A2 (es) 2023-02-16
CN115916188A (zh) 2023-04-04
CL2022002479A1 (es) 2023-08-18
JP7781764B2 (ja) 2025-12-08
EP4132515A1 (en) 2023-02-15
IL296075A (en) 2022-11-01
AR121566A1 (es) 2022-06-15
AU2021236340A1 (en) 2022-09-29
KR20230009873A (ko) 2023-01-17
US20230121547A1 (en) 2023-04-20

Similar Documents

Publication Publication Date Title
ZA202209989B (en) A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof
SG136804A1 (en) Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MXPA05012421A (es) Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos.
MX2020008906A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
EA202190662A1 (ru) Фармацевтические комбинации для лечения опухоли, содержащие антитело к cd19 и естественные клетки-киллеры
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
UY27812A1 (es) Uso de docetasel-doxorubin-ciclofosfamida como apoyo de terapias
NO20054988D0 (no) Preparater og metoder for behandling av cancer
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
MX2020006042A (es) Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas.
MX2020009773A (es) Terapia de combinacion.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
CY1111565T1 (el) Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11
WO2022271810A3 (en) Bicyclic peptidyl pan-ras inhibitors
MX2021000726A (es) Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer.
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
PH12022552710A1 (en) Anti-flt3 antibodies and compositions
MA69153A1 (fr) Méthodes de traitement d'une splénomégalie
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.
PH12022551008A1 (en) Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
MX2022005032A (es) Terapia secuencial anti cumulo de diferenciacion 19 (cd19).